Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,711 | 318 | 2,351 |
| Samples | 1,175 | 185 | 972 |
| Peptides | 1,131 | 136 | 991 |
Function
ATRX · ATRX chromatin remodeler
The protein encoded by this gene contains an ATPase/helicase domain, and thus it belongs to the SWI/SNF family of chromatin remodeling proteins. This protein is found to undergo cell cycle-dependent phosphorylation, which regulates its nuclear matrix and chromatin association, and suggests its involvement in the gene regulation at interphase and chromosomal segregation in mitosis. Mutations in this gene are associated with X-linked syndromes exhibiting cognitive disabilities as well as alpha-thalassemia (ATRX) syndrome. These mutations have been shown to cause diverse changes in the pattern of DNA methylation, which may provide a link between chromatin remodeling, DNA methylation, and gene expression in developmental processes. Multiple alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2017].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1121 amino-acid changes on canonical ENST00000373344 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ATRX · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ATRX – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 59/612 10% |
| Oral Cavity Carcinoma | 4/54 7% | 0/0 0% |
| Burkitts Lymphoma | 10/32 31% | 3/196 2% |
| Cervical Carcinoma | 4/35 11% | 19/422 4% |
| Osteosarcoma | 3/45 7% | 7/166 4% |
| Small Cell Lung Carcinoma | 4/9 44% | 32/752 4% |
| Melanoma | 12/210 6% | 87/1899 5% |
| Colorectal Carcinoma | 29/143 20% | 128/3239 4% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Glioma | 0/52 0% | 91/2127 4% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 52/1390 4% |
| Bladder Carcinoma | 3/58 5% | 32/956 3% |
| Gastric Carcinoma | 4/74 5% | 58/1809 3% |
| Ovarian Carcinoma | 14/109 13% | 21/998 2% |
| Neuroendocrine Tumour | 10/154 6% | 13/577 2% |
| Other Solid Cancers | 3/94 3% | 46/1515 3% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 24/810 3% |
| Head and Neck Carcinoma | 5/85 6% | 40/1574 3% |
| Unknown | 1/10 10% | 0/29 0% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Other Sarcomas | 0/69 0% | 17/699 2% |
| Ewings Sarcoma | 5/63 8% | 1/262 0% |
| Breast Carcinoma | 8/144 6% | 51/3264 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Biliary Tract Carcinoma | 0/54 0% | 15/950 2% |
| Rhabdomyosarcoma | 3/33 9% | 0/171 0% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Hepatocellular Carcinoma | 0/46 0% | 32/2210 1% |
Mutation Distribution
Where ATRX is mutated · all tissues, split by cell line vs tissue
How many mutations in ATRX were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,711 mutations in ATRX
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|